ORIC
Oric Pharmaceuticals, Inc.
$7.53
+0.40%
$828.1M
No data for this timeframe.
Vol
Market Cap$828.1M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders7 funds
Inst. Value$81.8M
Inst. Activity4 buys / 0 sells
Reddit Sentiment50° Neutral
SEC Reports1
Press Releases1
Recent Activity
Jun 5, 2026
other
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- OR
May 4, 2026
SEC
ORIC Pharmaceuticals reported Q1 2026 net loss of $35.8M ($0.34/share), missing consensus estimates of $0.31/share by 9.
8-K — Impact 4/10
Apr 3, 2026
Press
ORIC Pharmaceuticals announced the grant of stock options and restricted stock units to a new non-executive employee as
Impact 2/10
Feb 24, 2026
Insider
Piscitelli Dominic sold 52,000 shares
Chief Financial Officer @ $0.00 ($0.00)
Feb 24, 2026
Insider
Piscitelli Dominic sold 52,000 shares
Chief Financial Officer @ $4.36 ($226.7K)
Inst.
MORGAN STANLEY — ADD
1,194,073 shares ($9.8M)
Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
572,724 shares ($4.7M)
Price Targets
$20.36
+154.5% upside
Strong Buy
Current $8.00
Low $15.00
Median $21.00
High $25.00
14 analysts
$15.00
$25.00
Analyst Ratings
9Strong Buy
11Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 8, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 15, 2026 | Goldman Sachs | UPGRADE | Buy |
| May 5, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Apr 2, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 1, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.36 | $-0.40 — $-0.30 | 24% YoY | 14 |
| Next Q | $-0.37 | $-0.45 — $-0.30 | -12% YoY | 14 |
| Current FY | $-1.45 | $-1.66 — $-1.30 | 1% YoY | 14 |
| Next FY | $-1.55 | $-1.86 — $-1.20 | -7% YoY | 12 |
Latest Reports
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $37.2M | ADD |
| FMR LLC | $20.3M | — |
| MORGAN STANLEY | $9.8M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $5.1M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $4.7M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 24, 2026 | Piscitelli Dominic | M | $0.00 |
| Feb 24, 2026 | Piscitelli Dominic | M | $226.7K |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
7 institutional holders with $81.8M total value (9,998,821 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, MORGAN. Net buying activity: 4 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 4,541,974 | $37.2M | 45.4% | ADD +48.8% |
| 2 | FMR LLC | 2,478,922 | $20.3M | 24.8% | — |
| 3 | MORGAN STANLEY | 1,194,073 | $9.8M | 11.9% | ADD +60.2% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 621,086 | $5.1M | 6.2% | ADD +57.7% |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 572,724 | $4.7M | 5.7% | DOUBLED +3849.8% |
| 6 | BANK OF AMERICA CORP /DE/ | 507,510 | $4.2M | 5.1% | DOUBLED +390.6% |
| 7 | WELLS FARGO & COMPANY/MN | 82,532 | $675.1K | 0.8% | ADD +61.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 745,528 | 1,194,073 | +60.2% | $9.8M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 14,500 | 572,724 | +3849.8% | $4.7M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 103,450 | 507,510 | +390.6% | $4.2M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 50,963 | 82,532 | +61.9% | $675.1K | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 3,124,693 | 4,650,138 | +48.8% | $55.8M | 2025-Q3 |
| MORGAN STANLEY | ADD | 394,785 | 745,528 | +88.8% | $8.9M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 382,389 | 603,207 | +57.7% | $7.2M | 2025-Q3 |
| UBS Group AG | DOUBLED | 99,006 | 339,236 | +242.6% | $4.1M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 298,442 | 103,450 | -65.3% | $1.2M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 33,603 | 50,963 | +51.7% | $611.6K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 10,200 | 14,500 | +42.2% | $174.0K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 168,671 | 394,785 | +134.1% | $4.0M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 10,200 | — | $103.5K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 76,990 | 0 | -100.0% | $0.00 | 2025-Q2 |
| CITADEL ADVISORS LLC | DOUBLED | 47,626 | 525,889 | +1004.2% | $2.9M | 2025-Q1 |
| MORGAN STANLEY | TRIM | 347,355 | 168,671 | -51.4% | $941.2K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 139,683 | 76,990 | -44.9% | $429.6K | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 14,267 | 47,626 | +233.8% | $384.3K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 27,546 | 35,857 | +30.2% | $289.4K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 13,700 | 0 | -100.0% | $0.00 | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 410,229 | — | $4.2M | 2024-Q3 |
1 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 24, 2026 | Piscitelli Dominic | Chief Financial Officer | M | 52,000 | $0.00 | $0.00 |
| Feb 24, 2026 | Piscitelli Dominic | Chief Financial Officer | M | 52,000 | $4.36 | $226.7K |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 0 neutral. Avg impact: 4.0/10.
Current analyst consensus: Strong Buy (91% buy). Based on 22 analysts: 9 strong buy, 11 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$20.36 mean target
+154.5% upside
Strong Buy (1.25)
$15.00 Low
$25.00 High
| Metric | Value |
|---|---|
| Current Price | $8.00 |
| Target Low | $15.00 |
| Target Mean | $20.36 |
| Target Median | $21.00 |
| Target High | $25.00 |
| # Analysts | 14 |
| Recommendation | Strong Buy (1.25) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.36 | $-0.40 | $-0.30 | 23.8% | +0.0% | 2↑ 7↓ | $0.0B | 0.0% | 14 |
| Next Q 2026-09-30 |
$-0.37 | $-0.45 | $-0.30 | -12.0% | +0.0% | 3↑ 6↓ | $0.0B | 0.0% | 14 |
| Current FY 2026-12-31 |
$-1.45 | $-1.66 | $-1.30 | 1.1% | +0.0% | 2↑ 8↓ | $0.0B | 0.0% | 14 |
| Next FY 2027-12-31 |
$-1.55 | $-1.86 | $-1.20 | -6.7% | -0.2% | 4↑ 4↓ | $0.0B | 0.0% | 12 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.358 | |
| 7d ago | $-0.358 | |
| 30d ago | $-0.358 | |
| 60d ago | $-0.343 | -0.015 |
| 90d ago | $-0.343 | -0.015 |
5 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 8, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 15, 2026 | Goldman Sachs | UPGRADE | — | Buy |
| May 5, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Apr 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 1, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 13, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 24, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Feb 24, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 24, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Jan 13, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Jan 7, 2026 | Piper Sandler | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 9 | 11 | 2 | 0 | 0 | 91% | |
| May 1, 2026 | 9 | 10 | 2 | 0 | 0 | 90% | |
| Apr 1, 2026 | 9 | 10 | 2 | 0 | 0 | 90% | |
| Mar 1, 2026 | 9 | 10 | 2 | 0 | 0 | 90% | |
| Feb 1, 2026 | 9 | 10 | 2 | 0 | 0 | 90% | |
| Jan 1, 2026 | 9 | 9 | 2 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
1 mentions
0 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 1, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
01 APIRL 2026 , WHAT ARE THE BIGGEST WINNERS ?
▲ 1
💬 1
⚡ 0.5
Jun 5, 2026
other
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical
Jun 2, 2026
short_volume
Short Volume: ORIC — 57.9% short (1.2M / 2.1M)
Short: 1,197,005 | Exempt: 19,435 | TRF Vol: 2,067,511 | Short Ratio: 57.9% | Off-exchange volume (dark pool + OTC)
May 27, 2026
other
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
<p align="justify">SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical
May 11, 2026
earnings_calendar
ORIC Q1 2026 Earnings Scheduled — 2026-05-11
May 6, 2026
short_volume
Short Volume: ORIC — 56.3% short (0.3M / 0.6M)
Short: 324,204 | Exempt: 0 | TRF Vol: 575,765 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
May 4, 2026
earnings
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
<p align="center"><em>Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial i
May 4, 2026
earnings_calendar
ORIC Q1 2026 Earnings Scheduled — 2026-05-04
May 1, 2026
other
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical
May 1, 2026
short_interest
FTD: ORIC — 94,102 shares ($0.9M) failed to deliver
Settlement: 20260501, Price: $9.88, FTD Value: $929,727.76, ORIC PHARMACEUTICALS INC COM
Apr 22, 2026
short_volume
Short Volume: ORIC — 66.1% short (0.5M / 0.7M)
Short: 473,296 | Exempt: 0 | TRF Vol: 715,752 | Short Ratio: 66.1% | Off-exchange volume (dark pool + OTC)
Apr 17, 2026
routine
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting
<p align="justify">SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinic
Apr 10, 2026
short_volume
Short Volume: ORIC — 62.9% short (0.6M / 1.0M)
Short: 621,200 | Exempt: 0 | TRF Vol: 987,694 | Short Ratio: 62.9% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
short_interest
FTD: ORIC — 141,800 shares ($1.3M) failed to deliver
Settlement: 20260406, Price: $8.89, FTD Value: $1,260,602, ORIC PHARMACEUTICALS INC COM
Apr 3, 2026
regulatory
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinica
Apr 2, 2026
short_interest
FTD: ORIC — 300,200 shares ($2.2M) failed to deliver
Settlement: 20260402, Price: $7.48, FTD Value: $2,245,496, ORIC PHARMACEUTICALS INC COM